MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
PerkinElmer Accounts Receivables 2011-2026 | PKI
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables PerkinElmer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 783 M | 661 M | 662 M | 738 M | 1.18 B | - | 745 M | 633 M | 552 M | 439 M | - | 471 M | 470 M | 457 M | 357 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 B | 357 M | 626 M |
Quarterly Accounts Receivables PerkinElmer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 680 M | 661 M | 617 M | 632 M | 602 M | 597 M | 589 M | 633 M | 645 M | 627 M | 587 M | 613 M | 541 M | 932 M | 942 M | 1.18 B | 948 M | 993 M | 979 M | - | 798 M | 709 M | 626 M | 745 M | 725 M | 725 M | 725 M | 633 M | 633 M | 633 M | 633 M | 552 M | 552 M | 552 M | 552 M | 415 M | 443 M | 436 M | 437 M | - | 414 M | 426 M | 415 M | 471 M | 471 M | 471 M | 471 M | 467 M | 467 M | 467 M | 470 M | 457 M | 457 M | 457 M | 457 M | 357 M | 360 M | 383 M | 345 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 B | 345 M | 593 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aspira Women's Health
AWH
|
1.21 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Agilent Technologies
A
|
1.17 B | $ 116.73 | 2.5 % | $ 35.5 B | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 25.1 | 1.09 % | $ 697 M | USA |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Danaher Corporation
DHR
|
3.91 B | $ 196.39 | 2.82 % | $ 140 B | USA |
 |
Exact Sciences Corporation
EXAS
|
299 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
69 M | $ 16.2 | 1.85 % | $ 490 M | USA |
 |
CareDx, Inc
CDNA
|
42.6 M | $ 17.93 | 1.45 % | $ 955 M | USA |
 |
Guardant Health
GH
|
138 M | $ 94.2 | 0.96 % | $ 11.8 B | USA |
 |
DexCom
DXCM
|
1.22 B | $ 65.33 | 3.53 % | $ 25.5 B | USA |
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 15.99 | -0.62 % | $ 172 M |  China |
 |
Co-Diagnostics
CODX
|
190 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 107.95 | 0.74 % | $ 8.9 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
5.65 M | $ 2.0 | 0.25 % | $ 8.85 M | USA |
 |
Illumina
ILMN
|
735 M | $ 128.01 | 1.24 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | USA |
 |
IQVIA Holdings
IQV
|
3.4 B | $ 173.83 | 1.88 % | $ 29.9 B | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | China |
 |
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 275.0 | 2.17 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
359 M | $ 80.06 | 2.54 % | $ 5.4 B | USA |
 |
Charles River Laboratories International
CRL
|
709 M | $ 175.68 | 3.62 % | $ 8.71 B | USA |
 |
Medpace Holdings
MEDP
|
402 M | $ 521.98 | 2.65 % | $ 15.1 B | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K |  Israel |
 |
Mettler-Toledo International
MTD
|
778 M | $ 1 320.64 | 3.99 % | $ 27.2 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
115 M | $ 4.82 | 1.58 % | $ 446 M | USA |
 |
NeoGenomics
NEO
|
159 M | $ 8.27 | 2.54 % | $ 1.06 B | USA |
|
Biodesix
BDSX
|
8.6 M | $ 14.44 | -0.65 % | $ 1.87 B | USA |
 |
OpGen
OPGN
|
29.3 K | - | -16.95 % | $ 1.54 M | USA |
 |
Natera
NTRA
|
244 M | $ 211.74 | 1.18 % | $ 20.8 B | USA |
 |
Pacific Biosciences of California
PACB
|
35.4 M | $ 1.47 | 2.15 % | $ 441 M | USA |
 |
Quotient Limited
QTNT
|
5.32 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Precipio
PRPO
|
1.98 M | $ 28.05 | -1.58 % | $ 45 M | USA |
 |
Personalis
PSNL
|
8.14 M | $ 6.42 | 4.05 % | $ 380 M | USA |
 |
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
173 K | $ 2.7 | 0.37 % | $ 87.6 K | USA |
 |
Biomerica
BMRA
|
731 K | $ 2.16 | - | $ 4.96 M | USA |
 |
BioNano Genomics
BNGO
|
5.2 M | $ 1.18 | 0.43 % | $ 6.43 M | USA |